The city of Washington, District Of Columbia, currently has 164 active clinical trials seeking participants for Cancer research studies.
Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body
Recruiting
This phase III trial studies how well the addition of radiotherapy to the usual treatment (chemotherapy) works compared to the usual treatment alone in treating patients with esophageal and gastric cancer that has spread to a limited number of other places in the body (oligometastatic disease). Radiotherapy uses high energy x-rays, gamma rays, or protons to kill tumor cells and shrink tumors. Drugs used in usual chemotherapy, such as leucovorin, 5-fluorouracil, oxaliplatin, and capecitabine, wor... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/15/2023
Locations: MedStar Georgetown University Hospital, Washington, District of Columbia
Conditions: Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Oligometastatic Esophageal Adenocarcinoma, Oligometastatic Gastric Adenocarcinoma, Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8
Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer
Recruiting
This research study is looking to see whether the combination of Dostarlimab and Niraparib plus Radiation Therapy (RT) is safe and effective in participants with metastatic triple negative breast cancer. The names of the study treatment involved in this study are: Dostarlimab Niraparib Radiation Therapy (RT), which is given per standard of care.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/13/2023
Locations: Sibley Memorial Hospital, Washington, District of Columbia
Conditions: Breast Cancer, Triple Negative Breast Cancer
Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study
Recruiting
This phase III trial compares the effect of active symptom monitoring and patient education to patient education alone in helping young women with stage I-III breast cancer stay on their hormone therapy medicines. The patient education tool contains interactive weblinks which provide patients with education material about breast cancer and side effects of therapy. Symptom monitoring is a weblink via email or text message with questions asking about symptoms. Hormone therapy for breast cancer can... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
11/09/2023
Locations: Kaiser Permanente-Capitol Hill Medical Center, Washington, District of Columbia
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Hormone Receptor-Positive Breast Carcinoma
Evaluating Safety and Efficacy of Prostate-sparing Radical Cystectomy
Recruiting
The purpose of this clinical trial is to determine if prostate-capsule-sparing cystectomy improves functional outcomes without comprising oncologic outcomes in male patients receiving a radical cystectomy. Patients will be randomized to one of two groups: prostate capsule-sparing radical cystectomy or nerve-sparing radical cystectomy. Patients will be monitored following standard of care guidelines and clinical data will be collected. Patients in both groups will be asked to complete an erectile... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
11/01/2023
Locations: Sibley Memorial Hospital, Washington, District of Columbia
Conditions: Bladder Cancer
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
Recruiting
This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant prostate cancer. This trial will use olaparib or carboplatin as initial therapy with crossover to the alternate or second-line drug after first progression for patients with tumors containing BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L inactivating mutations. P... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
10/31/2023
Locations: Washington DC VA Medical Center, Washington, DC, Washington, District of Columbia
Conditions: Metastatic Castrate Resistant Prostate Cancer, BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L Mutations
Gender Related Coping and Survivorship for Genitourinary Cancers
Recruiting
This research is being done to learn more about coping and survivorship of women with bladder cancer, specifically regarding psychosocial distress and sexual dysfunction. This study is a non-therapeutic study and will randomize participants to a standard of care group and education group. Patients in both groups will be asked to complete surveys regarding their mood and sexual function. Patients in the intervention group will be asked to complete attendance diaries regarding educational and supp... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
10/23/2023
Locations: Sibley Memorial Hospital, Washington, District of Columbia
Conditions: Bladder Cancer
Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG
Recruiting
The purpose of this study is to evaluate mood changes in patients with Non-Muscle Invasive Bladder Cancer who are receiving intravesical Bacillus Calmete-Guerin (BCG). Patients with Non-Muscle Invasive Bladder Cancer receiving intravesical treatments are eligible to participate in this study. Participation involves providing research blood and urine samples prior to the start of treatment and throughout the treatment course. The study team will also collect participant's medical history and clin... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/23/2023
Locations: Sibley Memorial Hospital, Washington, District of Columbia
Conditions: Non-Muscle Invasive Bladder Cancer
The Selfie Study- Assessing Novel Markers for Cervical Cancer Screening From Self-collected Samples
Recruiting
Cervical cancer is primarily caused by Human Papillomaviruses (HPV). Testing for HPV in cervical samples is now an option for cervical cancer screening. HPV can also be tested from self-collected samples which may help to improve access to screening, since it does not require a doctor visit. However, many women will test positive for HPV who are not at high risk for cervical cancer. Therefore, additional ("triage") tests are needed to determine which women testing HPV-positive require additional... Read More
Gender:
Female
Ages:
Between 30 years and 69 years
Trial Updated:
10/23/2023
Locations: Medical Faculty Associates, Washington, District of Columbia
Conditions: Human Papilloma Virus, Cervical Cancer, CIN 2/3
Social Risk Factors and Discrimination in Cancer Survivorship
Recruiting
The objective of the proposed study is to scale social risk factor screening and referral for cancer survivors and to solidify information exchange between clinical and community settings in order to improve survivor health and well-being. This will be completed through three primary aims: 1) To ascertain workflow and map community resources needed to facilitate social risk factor screening and referral for breast and prostate cancer survivors in Washington, District of Columbia. 2) To determine... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/17/2023
Locations: MedStar Washington Hospital Center, Washington, District of Columbia
Conditions: Social Determinants of Health, Breast Cancer, Prostate Cancer, Health Equity, Disparities
Pembrolizumab and Lenvatinib in Advanced Cervical Cancer
Recruiting
This is a phase II trial of combination therapy of pembrolizumab and lenvatinib in patients with locally advanced or metastatic cervical cancer that had failed first line of therapy. The hypothesis is the combination of lenvatinib and pembrolizumab will overcome vascular endothelial growth factor (VEGF)-mediated immunosuppression to enhance the response of patients with locally advanced or metastatic cervical cancer.
Gender:
Female
Ages:
18 years and above
Trial Updated:
10/10/2023
Locations: MedStar Georgetown University Hospital, Washington, District of Columbia +1 locations
Conditions: Cervical Cancer, Metastatic Cervical Cancer
Device Feasibility and Acceptability to Improve Insomnia in Cancer
Recruiting
Sleep disruption is common among young adult cancer survivors for a variety of reasons. Cognitive behavioral therapy for insomnia (CBT-I) has been shown to improve chronic sleep disorders. This project will test the feasibility and acceptability of a new voice-activated virtual assistant (VAVA) device to deliver CBT-I to improve sleep among young adult cancer survivors with chronic sleep disorders.
Gender:
All
Ages:
Between 18 years and 39 years
Trial Updated:
10/04/2023
Locations: MedStar Washington Hospital Center, Washington, District of Columbia
Conditions: Cancer, Insomnia Chronic
NOURISH-T+: Promoting Healthy Eating and Exercise Behaviors
Recruiting
Pediatric cancer survivors are at an increased risk of excessive weight gain and reduced exercise behaviors with the potential for this risk to worsen over time. With over 80% of pediatric cancer patients living to adulthood, many pediatric cancer survivors experience long-term health consequences such as heart disease - the leading cause of death in this population. The purpose of this clinical research study is to teach parents/caregivers skills that will help prevent and reduce the problems... Read More
Gender:
All
Ages:
Between 5 years and 14 years
Trial Updated:
09/26/2023
Locations: Children's National Hospital, Washington, District of Columbia
Conditions: Obesity, Childhood, Cancer, Survivorship